Navigation Links
International Isotopes Inc. Announces First Quarter 2008 Financial Results
Date:5/12/2008

Revenue Increase 45% to $ 1.3 Million - Increases in Nearly All Business

Segments

IDAHO FALLS, Idaho, May 12 /PRNewswire-FirstCall/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces financial results for the first quarter ending March 31, 2008.

REVENUE: Revenue for the three-month period ended March 31, 2008 was $1,307,938 as compared to $902,632 for the same period in 2007, an increase of $405,306 or approximately 45%. The increase in total revenue was attributable to especially strong performance in cobalt products, radiochemical products, and radiological services business segments.

Revenue from the sale of cobalt products for the three-month period ending March 31, 2008 was $270,528 compared to $39,025 for the same period in 2007. This represents nearly a six fold increase in revenue in the segment and is attributable to increased sales of sealed cobalt sources and teletherapy capsules to numerous customers.

Revenue from the sale of radiochemical products for the three-month period ending March 31, 2008 was $318,408 compared to $225,914 for the same period in 2007. This represents an increase in revenue of $92,495 or nearly 41% and is attributable to increased sales of radiochemical iodine-131.

Revenue from the radiological services segment for the three-month period ending March 31, 2008 was $245,722 compared to $147,609 for the same period in 2007. This represents an increase in revenue of $98,113 or approximately a 66% and is primarily attributable to increased volumes of gemstone processing that have resulted following resolution of the regulatory issues that had limited revenues in this segment during 2007.

GROSS PROFIT: Gross profit for the three-month period ended March 31, 2008 was $698,402 (or 53% of revenue) compared to $373,613 (or 41% of revenue) for the same period in 2007. Operating expenses for the period were $1,145,507 for the three-month period ended March 31, 2008 compared to $920,825 for the same period of 2007. Although operating expense increased by $224,682, or 24%, in the period comparisons, it is important to note that when compared to revenue, operating expense actually declined as a percentage of revenue, from 102% of revenue for the three-month period ended December 31, 2007, to approximately 88% of revenue for the same period in 2008. The most significant factor in the increased operating expense was attributable to an increase in contract labor expense, and cost of stock option benefits during the period. Salaries and contract labor expenses totaled $512,612 for the three-month period ended March 31, 2008, as compared to $336,262 for the same period of 2007, an increase of $176,350 or 52% and primarily attributable to accounting methods of costing stock options. General and administrative (G&A) expense, for the three-month period ended March 31, 2008, were $617,167 as compared to $575,705 for the same period of 2007, an increase of $41,462 or 7%, and was attributable to small increases in salaries and additions to administrative staff.

NET LOSS: The Company's reported loss for the three-month period ended March 31, 2008 was $465,944, compared to a loss of $518,546 for the same period in 2007. This represents a decrease in loss of $52,608 for the periods in comparison. The major elements responsible for this decreased loss was increased revenue in the three major segments discussed above and the reduction in costs of goods sold that has resulted in improved gross profit performance, and reductions in operating costs as compared to the percentage of total revenue for the period.

Steve T. Laflin, President and CEO of International Isotopes Inc. said, "Most of our core business segments continue to demonstrate positive growth as the result of better market penetration and capitalizing upon market opportunities. The reduction in operating expense as compared to revenue is the result of increased efficiencies in operations. During this first quarter, the Company also continued to incur significant legal expenses for protection of intellectual property. I believe the results of this quarter are indicative of the positive trend in financial performance I expect to see for the remainder of the year. I am encouraged by these financial results and look forward to the remainder of the 2008. Company wide, to a person, we are dedicated to improving shareholder value."

International Isotopes Inc.

Three Months Ended March 31

2007 2008

Sales of Product $ 902,632 $1,307,938

Gross Profit $ 373,613 $698,402

Total Operating Expenses $920,825 $1,145,507

Operating (Loss) ($547,212) ($447,105)

Total Other Income (Expense) $28,666 ($18,839)

Net (Loss) ($518,546) ($465,944)

Net (Loss) Per Common Share

basic and diluted ($0.00) ($ 0.00)

Weighted Av. Share

Outstanding basic

and diluted 219,552,696 262,570,892

About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients.

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statement with respect to improving our financial performance and decreasing our operating expenses. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes, Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes, Inc.'s filings with the Securities and Exchange Commission at http://www.sec.gov, including our annual report on Form 10-KSB for the year ending December 31, 2007. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For More Information, Contact:

Steve Laflin, President and CEO

(208) 524-5300


'/>"/>
SOURCE International Isotopes Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast
2. Myanmar Government Must Cooperate With International Community to Ensure Appropriate Aid for Victims, Urges Amnesty International
3. International Diabetes Federation gives grant to Philippine diabetes education program
4. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America Healthcare Conference
5. World Vision International President Leaving Office in 2010
6. Lupus Organizations Issue International Call-to-Action to Combat Disease Affecting Five Million People
7. CalbaTech, Inc. Officially Changes Name to LifeStem International, Inc.; Lists New Symbol (LSTM) and Launches New Web Site
8. St. Davids HealthCare and Texas Cardiac Arrhythmia Announce International Center For Training, Research and Treatment of Heart Rhythm Disorders
9. Service Corporation International Announces Schedule for Its First Quarter 2008 Earnings Release and Conference Call
10. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
11. Internationally Renowned Plastic Surgery Coach Wendy Lewis Introduces Plastic Makes Perfect: The Complete Cosmetic Beauty Guide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Monica, CA (PRWEB) , ... May 03, 2016 , ... ... the highest quality medical providers to build the leading network of doctors and therapists ... Eric Nepomnaschy, D.C., founder of the distinguished Bay Chiropractic and Rehabilitation in ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution ... from a random library of sequences depending on their attraction for a target ... SELEX selection is commonly performed using filters, panning, or affinity chromatography separations. However, ...
(Date:5/3/2016)... FL (PRWEB) , ... May 03, 2016 , ... ... leading innovative specialty pharmacies, will be represented at the 2016 Asembia Specialty ... Vegas. The Asembia Summit is the largest U.S. health care conference for the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its ... situations or practice tricky or rare procedures in an environment that looks and feels ... is also available to inventors and “hackers” to develop and test new devices or ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... announces Benefits Alliance Insurance Services as the latest addition to its elite stable ... comprised of Partners Wayne Blasman, David Styles, and Paul Vincent. The Firm is ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology: